- 79-83% in normal testosterone (T) range (FDA requirement 75%)
- No patient elevated beyond normal range
- Androxal's impact on sperm concentration meets FDA non-inferiority threshold compared to placebo
- Potential key points of differentiation from gels
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Repros Therapeutics (RPRX) stock is dropping on Tuesday after the FDA asked the company to conduct an additional Phase 3 trial of its enclomiphene drug.